More on the TMC435 PILLAR study (from the PR in #msg-56129587):
Small and transient bilirubin elevations (direct and indirect) were seen in the TMC435 150mg dose groups.
This is essentially the same language as in prior press releases; we’ll presumably have to wait for the actual AASLD presentation to know if there’s a safety problem here.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.